The 2022–2023 ECDC PPS was the third EU-wide point prevalence survey of healthcare-associated infections and antimicrobial use in acute care hospitals.
This is a summary of the fourth joint inter-agency report on integrated analysis of antimicrobial consumption and occurrence of antimicrobial resistance in bacteria from humans and food-producing animals in the European Union (JIACRA IV – 2019–2021).
This report provides an integrated analysis of relationships between antimicrobial consumption in humans and food- producing animals and the occurrence of antimicrobial resistance in bacteria from humans and food- producing animals, respectively.
The main aim of the genomic study described in this surveillance report was to determine the distribution of the highly drug-resistant clade of Klebsiella pneumoniae (sequence type (ST) 39 in Greek hospitals in 2022.
In 2019, 8 874 (7.4%) of patients staying in an intensive care unit (ICU) for more than two days presented with at least one ICU-acquired healthcare-associated infection (HAI) under surveillance (pneumonia, bloodstream infection, or urinary tract infection).
The 2016–2017 ECDC point prevalence survey was the second EU-wide point prevalence survey of healthcare-associated infections and antimicrobial use in acute care hospitals.
This report is based on data for 2018-2020 retrieved on 13 February 2023 from The European Surveillance System (TESSy) and ECDC’s decentralised data storage for antimicrobial resistance and healthcare-associated infections (ARHAI). TESSy is a system for the collection, analysis and dissemination of data on communicable diseases.
This document presents the estimated incidence of bloodstream infections (BSI) with three key antibiotic-resistant bacteria, at country level in EU/EEA countries, using public data sources.
In 2016–2017, the European Centre for Disease Prevention and Control (ECDC) organised the third point prevalence survey (PPS) of healthcare-associated infections (HAIs) and antimicrobial use in European long-term care facilities (LTCFs) or HALT-3.